WINTON GROUP Ltd Has $6.69 Million Stake in BioMarin Pharmaceutical Inc. $BMRN

WINTON GROUP Ltd grew its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 2,835.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 123,474 shares of the biotechnology company’s stock after purchasing an additional 119,267 shares during the period. WINTON GROUP Ltd owned about 0.06% of BioMarin Pharmaceutical worth $6,687,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Quent Capital LLC bought a new position in BioMarin Pharmaceutical in the 3rd quarter valued at approximately $28,000. Smartleaf Asset Management LLC grew its stake in shares of BioMarin Pharmaceutical by 92.5% during the third quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company’s stock worth $40,000 after buying an additional 360 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of BioMarin Pharmaceutical by 62.2% during the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after buying an additional 295 shares in the last quarter. Employees Retirement System of Texas acquired a new position in shares of BioMarin Pharmaceutical during the second quarter worth $58,000. Finally, Jones Financial Companies Lllp lifted its stake in shares of BioMarin Pharmaceutical by 88.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,401 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 656 shares during the last quarter. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Stock Up 0.9%

Shares of NASDAQ:BMRN opened at $61.12 on Monday. The firm has a market cap of $11.75 billion, a P/E ratio of 34.34, a P/E/G ratio of 0.53 and a beta of 0.25. The company has a quick ratio of 3.50, a current ratio of 5.21 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical Inc. has a 12-month low of $50.76 and a 12-month high of $73.51. The business has a fifty day simple moving average of $58.92 and a 200 day simple moving average of $56.25.

Insider Activity

In related news, EVP Gregory R. Friberg sold 6,326 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $60.38, for a total value of $381,963.88. Following the transaction, the executive vice president directly owned 37,578 shares of the company’s stock, valued at $2,268,959.64. The trade was a 14.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.85% of the stock is owned by company insiders.

Analyst Ratings Changes

BMRN has been the topic of a number of research reports. Oppenheimer reduced their price objective on BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 24th. Truist Financial increased their target price on BioMarin Pharmaceutical from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. Guggenheim cut their price target on BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Canaccord Genuity Group upped their price objective on BioMarin Pharmaceutical from $98.00 to $104.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of BioMarin Pharmaceutical in a report on Monday, December 29th. Fifteen equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $89.64.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.